BRX Pharmacy
Outcome
DEA revoked BRX Pharmacy's registration effective November 22, 2024, for filling controlled substance prescriptions from January 2022 through June 2023 with multiple unresolved red flags including dangerous high-dose combinations, late-fill patterns for chronic pain patients, and opioid-OTC product bundles from a single prescriber.
Details
BRX Pharmacy — DEA Revocation for Multiple Red Flag Failures (2022–2024)
Outcome: DEA Administrator Anne Milgram signed the Decision and Order revoking BRX Pharmacy's registration effective November 22, 2024, after finding that between January 2022 and June 2023 the pharmacy repeatedly filled controlled substance prescriptions with multiple unresolved red flags of abuse and diversion.
BRX Pharmacy, located in Texas, was investigated by DEA and found to have filled controlled substance prescriptions with multiple simultaneous red flags during an 18-month period from January 2022 through June 2023.
The DEA's findings identified three categories of red flag failures. First, the pharmacy failed to identify and resolve the red flag of similar prescriptions combining controlled substances with over-the-counter products. Specifically, BRX filled prescriptions written by Dr. V.M. for eleven individuals for opioids in combination with non-steroidal anti-inflammatory drugs, muscle relaxers, laxatives, and multi-vitamins — suggesting these prescriptions were generated from a templated prescribing pattern rather than individualized clinical need.
Second, BRX repeatedly filled controlled substance prescriptions for individuals who were filling their chronic pain prescriptions late — consistently picking up their medications later than expected for someone with ongoing, chronic pain conditions. This pattern of late fills suggested the controlled substances were not being used for the stated pain management purpose.
Third, the pharmacy dispensed high doses of controlled substances that, in combination with other co-prescribed substances, could cause respiratory depression, coma, or death — without documenting resolution of the dangerous combination red flag before dispensing.
Primary Source: BRX Pharmacy; Decision and Order (Fed. Reg. Oct. 23, 2024)
How Crucible Prevents This
DEA found BRX filled prescriptions for patients who were consistently picking up chronic pain controlled substances late — an unusual behavior pattern that undermines the stated chronic pain therapeutic purpose. Crucible's refill timing analytics would have flagged patients whose chronic pain prescriptions were systematically delayed, suggesting the prescriptions were not being used for ongoing pain management.
Don't let this happen to your organization. See how Crucible works.
See How Crucible Works